IDEXX Laboratories Financial Statements
NASDAQ: IDXXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEXX Laboratories revenue and earnings
In fiscal 2025, IDEXX Laboratories generated $4.30 billion in revenue, up 10.4% from fiscal 2024, its 17th consecutive year of revenue growth. Net income was $1.06 billion (+19.3% year over year), for a net margin of 24.6% versus a median of 22.8% in the prior 5 years. Gross margin was 61.8% (up from 61.0%) and operating margin 31.6%.
Diluted earnings per share came in at $13.08, up from $10.67. Over the last 5 fiscal years, IDXX's revenue has grown at a 9.7% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
IDEXX Laboratories income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.30B | 3.90B | 3.66B | 3.37B | 3.22B | 2.71B | 2.41B | 2.21B | 1.97B | 1.78B |
| Revenue growth (YoY) | +10.42% | +6.46% | +8.72% | +4.73% | +18.79% | +12.45% | +8.75% | +12.40% | +10.91% | +10.83% |
| Cost of Revenue | 1.64B | 1.52B | 1.47B | 1.36B | 1.33B | 1.14B | 1.04B | 971.70M | 871.68M | 799.99M |
| Gross Profit | 2.66B | 2.38B | 2.19B | 2.00B | 1.89B | 1.57B | 1.37B | 1.24B | 1.10B | 975.44M |
| Operating Expenses | 1.30B | 1.25B | 1.09B | 1.11B | 957.40M | 876.52M | 812.70M | 750.21M | 684.35M | 625.20M |
| Research & Development | 251.21M | 219.79M | 190.95M | 254.82M | 161.01M | 141.25M | 133.19M | 117.86M | 109.18M | 101.12M |
| Selling, General & Admin | 1.05B | 1.03B | 901.89M | 850.75M | 796.39M | 735.27M | 679.51M | 632.34M | 575.17M | 524.08M |
| Operating Income | 1.36B | 1.13B | 1.10B | 898.76M | 932.03M | 694.52M | 552.85M | 491.33M | 413.03M | 350.24M |
| Interest Expense | 38.85M | 31.20M | 41.58M | 39.86M | 29.81M | 33.13M | 31.05M | 34.74M | 37.23M | 32.05M |
| Pretax Income | 1.32B | 1.11B | 1.06B | 859.97M | 902.65M | 661.99M | 522.22M | 457.74M | 381.06M | 321.85M |
| Income Tax | 264.73M | 221.96M | 216.13M | 180.88M | 157.81M | 79.85M | 94.43M | 80.69M | 117.79M | 99.79M |
| Net Income | 1.06B | 887.87M | 845.04M | 679.09M | 744.85M | 581.78M | 427.72M | 377.03M | 263.14M | 222.04M |
| Net Income growth (YoY) | +19.33% | +5.07% | +24.44% | -8.83% | +28.03% | +36.02% | +13.44% | +43.28% | +18.51% | +15.60% |
| EPS (Basic) | 13.17 | 10.77 | 10.17 | 8.12 | 8.74 | 6.82 | 4.97 | 4.34 | 3.00 | 2.47 |
| EPS (Diluted) | 13.08 | 10.67 | 10.06 | 8.03 | 8.60 | 6.71 | 4.89 | 4.26 | 2.94 | 2.44 |
| Shares Outstanding (Basic) | 80.43M | 82.47M | 83.07M | 83.62M | 85.20M | 85.34M | 86.11M | 86.86M | 87.77M | 89.73M |
| Shares Outstanding (Diluted) | 81.03M | 83.25M | 83.98M | 84.60M | 86.57M | 86.72M | 87.54M | 88.47M | 89.57M | 90.88M |
| EBITDA | 1.51B | 1.26B | 1.21B | 1.01B | 1.04B | 790.52M | 640.86M | 574.51M | 496.17M | 428.46M |
| Gross Margin | 61.80% | 61.04% | 59.82% | 59.52% | 58.76% | 58.04% | 56.73% | 56.10% | 55.73% | 54.94% |
| Operating Margin | 31.60% | 28.95% | 29.97% | 26.69% | 28.99% | 25.66% | 22.97% | 22.20% | 20.98% | 19.73% |
| Net Margin | 24.62% | 22.78% | 23.08% | 20.17% | 23.17% | 21.49% | 17.77% | 17.04% | 13.36% | 12.51% |
This table shows 10 annual periods of IDEXX Laboratories's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow IDXX's reporting calendar. What is a income statement?